Why CVKD Stock surged +4.41% Today — RQD Quant Desk Flash

The Roarable RQD rating assigns CVKD a score of 32 out of 100 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are:

• Fundamental Cash Engine: 5 / 20 (ROIC -35%; FCF yield 0%). Per the Roarable RQD rating and market data, the company reports negative return on invested capital and no free-cash-flow yield, meaning the business is not currently generating cash returns on capital employed.
• Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). The pillar is weak, and the holders section contains no institutional data to confirm or refute accumulation.
• Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). The pillar is weak; the holders section does not provide transaction detail.
• Macro Regime Fit: 9 / 20 (Beta 1.0; sector sensitivity). Beta of 1.0 indicates market-level volatility sensitivity; the pillar score reflects a below-midpoint fit.
• Forensic Balance Sheet: 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Per the Roarable RQD rating, these forensic metrics are mixed-to-weak, with the Piotroski F-Score at the low end.

For a prospective investor evaluating the stock today, the upside case rests almost entirely on non-financial catalysts (see Recent Catalysts) rather than on earnings power, which is absent. The valuation tradeoff is that a $0.94 share price against a $3.4M market capitalization prices the company as a high-risk option, while the reported losses and negative ROIC indicate that a continued cash burn could pressure the equity further. The RQD grade signals that the forensic and fundamental profile does not currently support a constructive view.

Cadrenal Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The source data does not describe the company's specific products, customers, or revenue model. Reported revenue is $0.0M across the FY 2023 through FY 2025 periods (per the SEC financials), which indicates the company is not currently generating product or service revenue in the reported periods.

Per the SEC financials, operating losses widened from $-7.6M in FY 2023 to $-13.5M in FY 2025, and cash declined from $10.0M to $4.0M over the period shown. Gross, operating, and net margins are each reported as 0% (per market data), consistent with zero revenue. ROIC is -35% (per market data). The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, and Debt/Equity is 0.5 (per the Roarable RQD rating); the balance sheet posture is therefore weak on the Piotroski measure while the Altman figure sits in a moderate range. Debt is reported as N/A in each period.

• Partnering interest (GREEN, CATALYST): A Stock Titan item reports that potential partners have shown strong interest and the company is evaluating possible deals. This is the only item flagged as a catalyst in the feed; deal terms and timing are not in the source data.
• Executive equity grants (YELLOW, MARKET WIRE): Reports describe a COO grant of 150,000 fully vested stock options and a CEO grant of 200,000 fully vested options with a $0.91 exercise price (per the news feed). These are compensation disclosures, not operating developments.
• Earnings preview (YELLOW, MARKET WIRE): A TradingView item lists a Q3'26 revenue estimate of 0 USD.
• Generic market-wire items (YELLOW, MARKET WIRE): Yahoo! Finance Canada and TradingView items cover market action and positioning without specific new facts.

Risk watch items: the feed contains no clinical, regulatory, or financing events beyond the partnering commentary. The butterfly supply-chain graph contains no proprietary signals (see below).

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. The only sector context provided is the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification. A prospective investor should note that the absence of mapped links means the source cannot quantify ripple effects from partner deals, supplier dependencies, or competitor developments.

• What specific products or clinical programs does the company have, and what is their development stage? The source data does not describe them.
• What are the terms and timing of the potential partnering deals referenced in the news feed?
• How does the company fund its operating losses beyond current cash of $4.0M, and does the reported debt position of N/A reflect no borrowings or missing disclosure?
• What explains the decline in cash from $10.0M to $4.0M and the widening operating losses between FY 2023 and FY 2025?
• Why are EPS, P/E, and EV/EBITDA unavailable, and what would those metrics show given the reported net losses?